Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment. - Wikidata - wikimedia - TriplyDB

Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.

Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.

http://www.wikidata.org/entity/Q33442358

about

Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML).

P2860

Q55283900-78DD5948-F72F-490C-9722-4E80C61A1E54

P2860

Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.

http://www.wikidata.org/entity/Q33442358

description

2017 nî lūn-bûn

@nan

2017 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Influence of cytarabine metabo ...... leukemia induction treatment.

@ast

Influence of cytarabine metabo ...... leukemia induction treatment.

@en

type

label

Influence of cytarabine metabo ...... leukemia induction treatment.

@ast

Influence of cytarabine metabo ...... leukemia induction treatment.

@en

prefLabel

Influence of cytarabine metabo ...... leukemia induction treatment.

@ast

Influence of cytarabine metabo ...... leukemia induction treatment.

@en

P1433

Q33442358-E42814BC-F085-49C2-92A2-1C0F73097F88

P1476

Q33442358-E03B6DDB-036B-4DD8-9789-068C25385757

P2093

Q33442358-2416B46B-E21F-46E3-865A-8C8078DACA29

Q33442358-3FF61CEB-7CA4-472E-AD79-6841913A5FA5

Q33442358-40F653D2-37F2-4909-9B18-C25911DC3D9D

Q33442358-681F0259-3D28-4930-892C-F1038C70A474

Q33442358-68B44D00-008B-4086-B9A2-CE490F8157E3

Q33442358-6E6B9FBD-CCB5-4B25-9A51-B19C1419AF08

Q33442358-A91C9F0A-8C70-4F5C-B6AD-0B5943E90FA1

Q33442358-C6281765-90E2-4451-B0F3-4CF440FCF694

Q33442358-CBCF956E-1295-4C0F-8732-5375824DA83B

Q33442358-DB3F15F3-2BDD-4E44-A7C6-2667DEA924CD

P2860

Q33442358-083D96C4-B7D4-4545-9727-3CB1DEC1BF9F

Q33442358-13D24A3D-ACA4-4EE6-9FF5-7B7EC053A51C

Q33442358-1C3F466D-473E-4C8C-808A-B2034B0E4430

Q33442358-20A63477-2480-43E0-9DDF-15900F6D3FF0

Q33442358-223CD248-AC05-451B-9C6B-E5485E793E06

Q33442358-25036B44-5BAA-4E41-9D41-A337685DD272

Q33442358-368CBC1F-B2F6-4ABB-A55D-FCB59AE17873

Q33442358-39CC6DE9-208E-40C0-B952-E9848A4E8DE1

Q33442358-45738DD6-4D81-4069-9067-38A65F5742B5

Q33442358-45EE5286-A7D3-474A-8A2E-B0DF3A2859AF

P304

Q33442358-2DECE1FD-6860-43E1-88EC-C52DB43C2257

P31

Q33442358-19CC87D5-0C5D-456A-8422-73A35B74EEF0

P356

Q33442358-926A5417-D050-4E2C-BCCA-9763FF2ACE2C

P433

Q33442358-496D2F52-3312-4F14-A894-0C960AA3C7AD

P478

Q33442358-D8546313-65A5-4620-971D-7A3BAAC7C744

P50

Q33442358-A3D41E7E-D600-49B7-A9FD-A00AF7BBE195

Q33442358-AD994DCA-F36D-4EC7-A287-1C411F54B0A8

P577

Q33442358-39A52259-9D66-456E-B81D-5D647E99D050

P698

Q33442358-A73E80E4-2C0B-4FEB-8B5C-7221CABE8F0E

P356

10428194.2017.1323267

P1433

Leukemia & Lymphoma

P1476

Influence of cytarabine metabo ...... leukemia induction treatment.

@en

P2093

Blanca Boluda

http://www.w3.org/2001/XMLSchema#string

David Martínez-Cuadrón

http://www.w3.org/2001/XMLSchema#string

Federico Moscardó

http://www.w3.org/2001/XMLSchema#string

José Cervera

http://www.w3.org/2001/XMLSchema#string

José Luis Poveda

http://www.w3.org/2001/XMLSchema#string

Luis Rojas

http://www.w3.org/2001/XMLSchema#string

Luis Sendra

http://www.w3.org/2001/XMLSchema#string

María José Herrero

http://www.w3.org/2001/XMLSchema#string

Pau Montesinos

http://www.w3.org/2001/XMLSchema#string

Rebeca Rodríguez-Veiga

http://www.w3.org/2001/XMLSchema#string

P2860

Reporting results of cancer treatment

Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia.

Effect of genetic alterations of cytarabine- metabolizing enzymes in childhood acute lymphoblastic leukemia.

The impact of CDA A79C gene polymorphisms on the response and hematologic toxicity in gemcitabine-treated patients: a meta-analysis.

Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.

Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia.

Potential mechanisms of resistance to cytarabine in AML patients.

The 5'-nucleotidases as regulators of nucleotide and drug metabolism.

Role of Genetic Polymorphisms of Deoxycytidine Kinase and Cytidine Deaminase to Predict Risk of Death in Children with Acute Myeloid Leukemia.

The influence of cytidine deaminase -33delC polymorphism on treatment outcome with high-dose cytarabine in Chinese patients with relapsed acute myeloid leukaemia.

P304

2880-2894

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428194.2017.1323267

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

J E Megías-Vericat

P577

2017-06-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28573946

http://www.w3.org/2001/XMLSchema#string